Glaukos Co. (NYSE:GKOS – Get Free Report) Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Glaukos Price Performance
Shares of NYSE:GKOS opened at $126.28 on Friday. The company has a market capitalization of $6.94 billion, a P/E ratio of -43.85 and a beta of 1.03. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $136.60. The firm’s 50 day simple moving average is $124.45 and its two-hundred day simple moving average is $109.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company’s revenue was up 19.0% on a year-over-year basis. During the same period last year, the firm earned ($0.55) EPS. Research analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On Glaukos
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on GKOS shares. Morgan Stanley boosted their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Stifel Nicolaus upped their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company upped their price target on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, BTIG Research raised their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.82.
View Our Latest Report on Glaukos
Glaukos Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Recommended Stories
- Five stocks we like better than Glaukos
- Are Penny Stocks a Good Fit for Your Portfolio?
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- 3 Warren Buffett Stocks to Buy Now
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.